Drug
Remogliflozin etabonate clinical trials
Also written GSK189075.
- studies test it
- 16
- open now
- 0
- in phase 3
- 0
- first study started
- 2004
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
16 studies that test it; most in 2007 (9)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2006 | 3 |
| 2007 | 9 |
| 2008 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 16 · Other 0
Often tested with
Tested in the same studies.
GW869682 (1) · Norethindrone acetate, ethinyl estradiol, ferrous fumarate drug combination (1) · Ethinyl Estradiol/Norethindrone (1) · Metformin (1) · Ketoconazole (1) · Hydrochlorothiazide (1) · Furosemide (1)
Studies
Open first, then newest update. How each study uses remogliflozin etabonate is read from its arms, and is right about nine times in ten.
Testing it · 16
- Dose-Ranging Study in Treatment Naive Type 2 Diabetes Mellitus(T2DM)CompletedPhase 2GlaxoSmithKlineNCT00500331Written as GSK189075
- Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-NaiveCompletedPhase 2GlaxoSmithKlineNCT00495469Written as GSK189075
- A Study to Assess the Safety of Single Doses of GSK189075 in Subjects With Type 1 Diabetes MellitusCompletedPhase 2GlaxoSmithKlineNCT00575159Written as GSK189075
- A Study To Assess The Safety And Tolerability Of GSK189075 When Given With A Total Daily Dose Of >/ 2000mg of MetforminCompletedPhase 1GlaxoSmithKlineNCT00519480Written as GSK189075
- A Study to Assess the Safety of Repeated Doses of GSK189075 and WELLBUTRIN SR in Healthy Male SubjectsCompletedPhase 1GlaxoSmithKlineNCT00625859Written as GSK189075
- Investigation Of Weight Loss And Body Composition Changes After Dosing With Either Placebo Or One Of Two Active DrugsCompletedPhase 1GlaxoSmithKlineNCT00494767Written as GSK189075
- GSK189075, GW869682 Or Placebo In Type 2 Diabetic PatientsCompletedPhase 2GlaxoSmithKlineNCT00291356Written as GSK189075 oral tablets
- A Study to Evaluate and Study Drug Levels in Blood Plasma When Giving High Doses of GSK189075 to Healthy VolunteersCompletedPhase 1GlaxoSmithKlineNCT00501930Written as GSK189075
- A Study of the Effects of GSK189075 on PK Profiles of an Oral Contraceptive Pill When Given to Healthy Female VolunteersCompletedPhase 1GlaxoSmithKlineNCT00504816Written as GSK189075
- Drug Interactions From Simultaneous Administration Of Metformin And GSK189075 To Subjects With Type 2 DiabetesCompletedPhase 1GlaxoSmithKlineNCT00376038Written as GSK189075 oral tablets
- A Study to Compare the Safety and Drug Levels in Blood When Using Various Forms of GSK189075 Given to Healthy SubjectsCompletedPhase 1GlaxoSmithKlineNCT00559884Written as GSK189075 (Modified and immediate release formulations)
- A Study of the Effects of Ketoconazole Taken Orally Has on the PK Profiles of a Dose of GSK189075 in Healthy VolunteersCompletedPhase 1GlaxoSmithKlineNCT00501397Written as GSK189075
- A First-time-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of GSK189075A in Healthy Subjects and in Subjects With Type 2 Diabetes MellitusCompletedPhase 1GlaxoSmithKlineNCT01571661Written as GSK189075A
- A Comparison Of Study Drug Blood Levels After One Dose Of GSK189075 In Subjects With Normal And Reduced Kidney FunctionCompletedPhase 1GlaxoSmithKlineNCT00501462Written as GSK189075
- A Study to Compare the Effect on Heart Rhythm of 3 Days of GSK189075, Placebo, or Moxifloxacin in Healthy AdultsCompletedPhase 1GlaxoSmithKlineNCT00532610Written as GSK189075
- A Study To Compare Effects Of GSK189075 In Combination With Either Furosemide Or HydrochlorothiazideCompletedPhase 1GlaxoSmithKlineNCT00671424Written as Remogliflozin etabonate (GSK189075)
Codes
What other systems call remogliflozin etabonate · ClinicalTrials.gg INT005335
- MeSH (NLM) C532127remogliflozin etabonateOne source NLM
- UNII (FDA) TR0QT6QSULREMOGLIFLOZIN ETABONATEConfirmed FDA, NLM, Wikidata
- Wikidata Q7312052remogliflozin etabonateConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C91023Remogliflozin EtabonateOne source FDA
- DrugBank DB12935One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C532127 | remogliflozin etabonate | One source NLM |
| UNII (FDA) | TR0QT6QSUL | REMOGLIFLOZIN ETABONATE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q7312052 | remogliflozin etabonate | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C91023 | Remogliflozin Etabonate | One source FDA |
| DrugBank | DB12935 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.